- Home
- FOSL vs CHRS Comparison
FOSL vs CHRS Comparison
Compare FOSL & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOSL
- CHRS
- Stock Information
- Founded
- FOSL 1984
- CHRS 2010
- Country
- FOSL United States
- CHRS United States
- Employees
- FOSL N/A
- CHRS N/A
- Industry
- FOSL Consumer Specialties
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FOSL Consumer Discretionary
- CHRS Health Care
- Exchange
- FOSL Nasdaq
- CHRS Nasdaq
- Market Cap
- FOSL 100.0M
- CHRS 112.5M
- IPO Year
- FOSL 1993
- CHRS 2014
- Fundamental
- Price
- FOSL $1.50
- CHRS $0.77
- Analyst Decision
- FOSL
- CHRS Buy
- Analyst Count
- FOSL 0
- CHRS 3
- Target Price
- FOSL N/A
- CHRS $4.68
- AVG Volume (30 Days)
- FOSL 402.4K
- CHRS 1.5M
- Earning Date
- FOSL 05-14-2025
- CHRS 05-12-2025
- Dividend Yield
- FOSL N/A
- CHRS N/A
- EPS Growth
- FOSL N/A
- CHRS N/A
- EPS
- FOSL N/A
- CHRS N/A
- Revenue
- FOSL $1,123,399,000.00
- CHRS $272,251,000.00
- Revenue This Year
- FOSL N/A
- CHRS N/A
- Revenue Next Year
- FOSL N/A
- CHRS $19.78
- P/E Ratio
- FOSL N/A
- CHRS N/A
- Revenue Growth
- FOSL N/A
- CHRS 19.87
- 52 Week Low
- FOSL $0.86
- CHRS $0.66
- 52 Week High
- FOSL $2.61
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- FOSL 58.14
- CHRS 39.79
- Support Level
- FOSL $1.42
- CHRS $0.74
- Resistance Level
- FOSL $1.63
- CHRS $0.82
- Average True Range (ATR)
- FOSL 0.13
- CHRS 0.06
- MACD
- FOSL -0.01
- CHRS -0.00
- Stochastic Oscillator
- FOSL 54.90
- CHRS 25.45
About FOSL Fossil Group Inc.
Fossil Group Inc is a design, innovation and distribution company in consumer fashion accessories. The products include traditional watches, smartwatches, jewelry, handbags, small leather goods, belts and sunglasses. The reportable segments are comprised of 1) Americas segment includes sales in Canada, Latin America and the United States. 2) Europe segment includes sales in European countries, the Middle East and Africa. 3) Asia segment includes sales in Australia, China, India, Indonesia, Japan, Malaysia, New Zealand, Singapore, South Korea and Thailand. Each reportable operating segment includes sales to wholesale and distributor customers, and sales through Company-owned retail stores and e-commerce activities based on the location of the selling entity.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.